Bright Minds Biosciences Inc.

As of June 30, 2026, Bright Minds Biosciences Inc. carries a market capitalization of 1.00B, placing it among publicly traded companies globally. Its enterprise value stands at 693.07M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bright Minds Biosciences Inc.'s next confirmed earnings release is scheduled for December 17, 2026.

As of June 30, 2026, Bright Minds Biosciences Inc. has 9.81M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Bright Minds Biosciences Inc. maintains a current ratio of 121.97, meaning it holds 122.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Bright Minds Biosciences Inc. posted a negative return on equity (ROE) of -13.63, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -13.51, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 25.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Bright Minds Biosciences Inc.'s stock has declined approximately 13.75% over the past 52 weeks. The 50-day moving average sits at 88.64, while the 200-day moving average is 103.69.

Over the twelve months ended June 30, 2026, Bright Minds Biosciences Inc. generated - - in revenue and converted that into -24.51M in net income, yielding earnings per share of -2.85. EBITDA reached -39.25M, while operating income came in at -39.32M.

As of June 30, 2026, Bright Minds Biosciences Inc. holds 307.83M in cash and equivalents against 65,589.00 in total debt, resulting in a net debt position of -307.83M. Total book value stands at 307.79M, with working capital of 307.74M providing operational flexibility.

Bright Minds Biosciences Inc. produced -24.67M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -2.82: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -27.50, meaning Bright Minds Biosciences Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Bright Minds Biosciences Inc.'s most recent stock split took place on July 14, 2023 with a 5:1 split ratio.

As of June 30, 2026, Bright Minds Biosciences Inc. has an Altman Z-Score of 236.53, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.